Prostate Cancer Blog » DNDN http://prostatecancercommunity.com/blog Great Information on Prostate Cancer Sun, 11 Sep 2011 21:35:35 +0000 en hourly 1 http://wordpress.org/?v=3.3 Prostate Cancer Drug Improves Survival http://prostatecancercommunity.com/blog/prostate-cancer-treatment/prostate-cancer-drug-improves-survival http://prostatecancercommunity.com/blog/prostate-cancer-treatment/prostate-cancer-drug-improves-survival#comments Sun, 17 Jan 2010 16:56:04 +0000 admin http://prostatecancercommunity.com/blog/prostate-cancer-treatment/prostate-cancer-drug-improves-survival Dendreon said its prostate cancer treatment Provenge prolonged patient survival, providing fuel for a rally in its shares.

Duration : 0:4:51


]]> http://prostatecancercommunity.com/blog/prostate-cancer-treatment/prostate-cancer-drug-improves-survival/feed 4 Treating Cancer – Dendreon’s Provenge May Improve Survival Rate for Prostate Cancer http://prostatecancercommunity.com/blog/prostate-cancer-survival-rate/treating-cancer-dendreons-provenge-may-improve-survival-rate-for-prostate-cancer-2 http://prostatecancercommunity.com/blog/prostate-cancer-survival-rate/treating-cancer-dendreons-provenge-may-improve-survival-rate-for-prostate-cancer-2#comments Sat, 10 Oct 2009 14:11:51 +0000 admin http://prostatecancercommunity.com/blog/prostate-cancer-survival-rate/treating-cancer-dendreons-provenge-may-improve-survival-rate-for-prostate-cancer-2 Dendreon Corporation (NASDAQ:
DNDN) today announced that its pivotal Phase 3 IMPACT study of PROVENGE®
(sipuleucel-T) in men with advanced prostate cancer met its primary endpoint of
significantly improving overall survival compared to placebo. The data were presented at
the American Urological Association (AUA) Annual Meeting.

Duration : 0:3:14


]]> http://prostatecancercommunity.com/blog/prostate-cancer-survival-rate/treating-cancer-dendreons-provenge-may-improve-survival-rate-for-prostate-cancer-2/feed 1 Treating Cancer – Dendreon’s Provenge May Improve Survival Rate for Prostate Cancer http://prostatecancercommunity.com/blog/prostate-cancer-prognosis/treating-cancer-dendreons-provenge-may-improve-survival-rate-for-prostate-cancer http://prostatecancercommunity.com/blog/prostate-cancer-prognosis/treating-cancer-dendreons-provenge-may-improve-survival-rate-for-prostate-cancer#comments Tue, 16 Jun 2009 11:17:47 +0000 admin http://prostatecancercommunity.com/blog/prostate-cancer-prognosis/treating-cancer-dendreons-provenge-may-improve-survival-rate-for-prostate-cancer Dendreon Corporation (NASDAQ:
DNDN) today announced that its pivotal Phase 3 IMPACT study of PROVENGE®
(sipuleucel-T) in men with advanced prostate cancer met its primary endpoint of
significantly improving overall survival compared to placebo. The data were presented at
the American Urological Association (AUA) Annual Meeting.

Duration : 0:3:14


]]> http://prostatecancercommunity.com/blog/prostate-cancer-prognosis/treating-cancer-dendreons-provenge-may-improve-survival-rate-for-prostate-cancer/feed 1